The purpose of the ImproveCareNow Network is 'to transform the health, care and costs for all children and adolescents with Crohn’s disease and ulcerative colitis (Inflammatory Bowel Disease or IBD) by building a sustainable collaborative chronic care network. We are enabling patients, families, clinicians and researchers to work together in a learning health care system to accelerate innovation, discovery and the application of new knowledge.’
The ImproveCareNow Network has expanded to include 109 care centers with 30,000 patients and 1,200 clinicians, including 950 pediatric gastroenterologists.
As part of the ImproveCareNow Network, our team at UNMC and Children's is currently participating in the COMBINE Trial. This will study if treatment with a single anti-TNF medication (infliximab and adalimumab) or dual therapy that includes methotrexate is more effective in children with moderate to severe Crohn’s disease. COMBINE is the first study to look at this question in children with Crohn’s disease. We expect that 425 kids from across the US will enter the study. The results of this study can be used to help doctors choose medications that help children the most.